<DOC>
	<DOCNO>NCT01955668</DOCNO>
	<brief_summary>In Part A investigate safety tolerability AZD6738 give orally patient relapsed/refractory CLL , PLL B cell lymphoma . In Part B investigate safety tolerability AZD6738 give orally patient prospectively identify 11q deleted ATM deficient , relapsed/refractory CLL</brief_summary>
	<brief_title>AZD6738 First Time Patient Multiple Ascending Dose Study</brief_title>
	<detailed_description>In first time patient study , AZD6738 administer patient relapsed/refractory chronic lymphocytic leukaemia ( CLL ) , prolymphocytic leukaemia ( PLL ) B cell lymphoma , primarily determine safety tolerability AZD6738 . Pharmacokinetics AZD6738 potential biological activity also investigate . An oral formulation AZD6738 use . The start dose 20 mg twice daily ( BD ) escalate reach maximum tolerate dose patient define dose-limiting toxicity . A ' 3 week , 1 week ' schedule , deem optimal model data non-clinical study , use initially . Following dose escalation phase study , additional patient prospectively identify 11q-deleted ATM deficient relapsed/refractory CLL enrol dose expansion phase explore safety , tolerability , pharmacokinetics biological activity select dose ( ) /schedule ( ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure , sample analysis . 2 . For dose escalation phase , Part A , histological cytological confirmation relapse refractory B cell malignancy , include CLL , PLL , Burkitt lymphoma/Burkitt cell leukaemia , acute lymphocytic leukaemia , hairy cell leukaemia ( HCL ) aggressive indolent B cell lymphoma , consider appropriate conventional treatment . For dose expansion phase , Part B , histological cytological confirmation relapse refractory 11qdeleted ATMdeficient CLL , consider appropriate conventional treatment . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 deterioration previous 2 week estimate life expectancy great 16 week . 4 . Not know positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody . 5 . Females must use adequate contraceptive measure , must breast feeding must negative pregnancy test prior start dose childbearing potential must evidence nonchildbearing potential fulfil one follow criterion screen : Post menopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . Amenorrhoeic 12 month serum folliclestimulating hormone ( FSH ) , luteinizing hormone ( LH ) plasma oestradiol level postmenopausal range institution . 6 . Ability swallow retain oral medication 1 . Receiving , receive four week prior study entry ( sign consent ) , treatment malignancy . 2 . Receiving , receive four week prior study entry ( sign consent ) , corticosteroid ( dose &gt; 10 mg prednisone/day equivalent ) reason . 3 . A known hypersensitivity AZD6738 excipient product . 4 . Treatment investigational medicinal product ( IMP ) within 28 day prior sign consent . 5 . Receiving , receive , concomitant medication , herbal supplement and/or food significantly modulate CYP3A4 Pgp activity ( wash period two week , three week St. John 's Wort ) . Note include common azole antifungal , macrolide antibiotic . 6 . Impaired hepatic renal function demonstrate follow laboratory value : 1 . Albumin &lt; 33g/L 2 . AST ALT &gt; 2.5 x ULN 3 . Total bilirubin &gt; 1.5 x ULN 4 . Alkaline phosphatase &gt; 2.5 x ULN 5 . Glomerular filtration rate ( GFR ) &lt; 50 mL/min , assess use standard methodology investigate centre ( i.e . CockroftGault , MDRD CKDEPI formula , EDTA clearance 24 h urine collection ) 6 . Serum creatinine &gt; 1.5 x ULN 7 . Haematuria : +++ microscopy dipstick 8 . AST , ALT , ALP , bilirubin renal function , opinion investigator , unstable worsen 7 . INR &gt; 1.5 evidence impair hepatic synthesis function Persisting ( &gt; 8 week ) severe pancytopenia due previous therapy rather disease ( ANC &lt; 0.5 x 109/L platelet &lt; 50 x 109/L ) confirm via bone marrow biopsy , part normal clinical care , prior sign consent 8 . CNS involvement malignancy 9 . Cardiac dysfunction define : Myocardial infarction within six month study entry , NYHA Class II/III/IV heart failure , unstable angina , unstable cardiac arrhythmia reduce LVEF &lt; 55 % 10 . Any following cardiac criterion : 1 . Mean resting correct QT interval ( QTc ) &gt; 470 msec obtain 3 electrocardiogram ( ECGs ) 24 hour 2 . Any clinically important abnormality rhythm , conduction morphology rest ECG ( e.g. , complete leave bundle branch block , third degree heart block ) 3 . Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , immediate family history long QT syndrome unexplained sudden death 40 year age 11 . Patients risk brain perfusion problem , e.g. , carotid stenosis 12 . Patients relative hypotension ( &lt; 100/60 mm Hg ) clinically relevant orthostatic hypotension , include fall blood pressure &gt; 20mm Hg 13 . Uncontrolled hypertension require clinical intervention 14 . Any malignancy active treat within past three year , exception cervical intraepithelial neoplasia nonmelanoma skin cancer 15 . Refractory nausea vomiting , chronic gastrointestinal disease previous significant bowel resection would preclude adequate absorption AZD6738 16 . Patients uncontrolled seizure 17 . Active infection require systemic antibiotic , antifungal antiviral drug 18 . Concurrent severe and/or uncontrolled medical condition ( e.g. , severe COPD , severe Parkinson 's disease , active inflammatory bowel disease ) psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>11q-deleted relapsed/refractory chronic lymphocytic leukaemia</keyword>
	<keyword>Prolymphocytic leukaemia</keyword>
	<keyword>B cell lymphoma</keyword>
</DOC>